<DOC>
	<DOCNO>NCT02587169</DOCNO>
	<brief_summary>Phase I/II multicenter prospective trial nilotinib adriamycin neoadjuvant treatment liposarcoma leiomyosarcoma retroperitoneum . The main objective study improve relapse-free survival ( RFS ) overall survival ( OS ) decrease 50 % 30 % relapse percentage 5 year patient resect sarcoma retroperitoneum . Secondary objective include analysis antitumoral activity response rate ( RECIST tissular change ) , assessment positive correlation biomarkers clinical result , study long term overall survival , analysis safety profile nilotinib-adriamycin combination . The trial hypothesis nilotinib-adriamycin combination synergistic therefore good response result expect ( 20 % P0 40 % P1 ) . The study seek find positive correlation biomarkers clinical result retroperitoneal liposarcoma leiomyosarcoma treat mentioned combination . The study involve participation 20 hospital Spanish Sarcoma Group ( GEIS ) . The treatment consist 4 neoadjuvant cycle nilotinib-adriamycin patient resectable retroperitoneal sarcoma . The research comprise robust translational study well histological radiological review .</brief_summary>
	<brief_title>Trial Nilotinib Adriamycin Treatment Liposarcomas Leiomyosarcomas Retroperitoneum</brief_title>
	<detailed_description>The nilotinib-adriamycin combination give 4 cycle 21 day . In cycle , nilotinib administer fix dose 400 mg/12h orally 6 consecutive day ( 1-6 ) endovenous adriamycin ( 20 minute ) day 5 three level ( phase I , dosage 60 mg/m2 , 65 mg/m2 , 75 mg/m2 test determine recommend dose phase II ) . Phase I include patient retroperitoneal liposarcoma , retroperitoneal leiomyosarcoma chondrosarcoma . Phase II focus retroperitoneal liposarcoma leiomyosarcoma .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Retroperitoneal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients histological diagnosis well differentiated liposarcoma , dedifferentiate liposarcoma primary leiomyosarcoma retroperitoneum resectable . In phase I study recruit patient highgrade chondrosarcoma nonmesenchymal type . Age : 1870 year . Measurable disease , accord RECIST criterion . Functional status : 01 ( ECOG ) . Baseline medullar function ( hemoglobin &gt; 10 g/dL , leukocytes ≥ 3.000/mm3 , RAN≥ 1,5 x 109 /l , granulocytes ≥ 1.500/mm3 , platelet ≥ 100.000/mm3 ) . Patients alteration transaminases ≤ 2.5 time normal limit , bilirubin total ≤ LSN , CPK≤ 2.5 time normal limit , alkaline phosphatase ≤ 2.5 time normal limit creatinine value ≤ 1.6 mg/dL , accept . Cardiac function ( LVEF ) normal , consider normal range institution . The patient must voluntarily sign informed consent trial test , know he/she leave trial time , without consequence his/her posterior medical attention . Patients fertile age ( male female ) must use effective contraceptive method entry study trial . Moreover , woman must maintain contraceptive measure 5 month treatment . Pregnancy must rule though urine test ( negative pregnancy test ) study enrolment . Patients receive previous chemotherapy . Patient irradiated tumoral disease . Functional status &gt; 1 ( ECOG ) . Metastasis location . Bilirubin value normal level . Creatinine 1.6 mg/dL . History another oncological disease except basalioma situ cervical carcinoma adequately treat . Serious cardiovascular disease ( dyspnea &gt; = 2 NYHA , ie . ) Systemic pathology limit survival le 2 year , limit patient availability , , clinical judgement , may interfere significantly treatment toxicity . Bacterial , viral , uncontrolled mycotic infectious disease . Pregnant lactating patient . Psychological , family , sociological geographical situation allow protocol fulfilment inform consent signature . Patients currently involve clinical trial receive agent investigation . Patient participate clinical trial and/or receive agent investigation 30 day prior enrolment . Patients require treatment prolongation QT interval amiodarone , disopyramide , procainamide , quinidine , sotalol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>liposarcoma</keyword>
	<keyword>leiomyosarcoma</keyword>
	<keyword>retroperitoneum</keyword>
	<keyword>chondrosarcoma</keyword>
</DOC>